Why the study?
Does biweekly-designed CT130 with drug-free intervals improve weight loss, lipid regulation, receptor homeostasis, and gastrointestinal tolerability compared to semaglutide in preclinical obesity models?
Does biweekly-designed CT130 with drug-free intervals improve weight loss, lipid regulation, receptor homeostasis, and gastrointestinal tolerability compared to semaglutide in preclinical obesity models?
Answers are grounded in this paper and cite their sources.
Preclinical evaluation of CT130 demonstrates that incorporating drug-free intervals into a long-acting GLP-1R agonist preserves receptor homeostasis, alleviates constipation-related stool dehydration, and enhances weight and cholesterol reduction via SREBP-2/PCSK9 decoupling compared to continuous semaglutide exposure.
AIM: To develop a next-generation, longer-acting, more-clinical-benefits agonist to achieve sustained efficacy with improved tolerability. METHODS: CT130 was designed from semaglutide. Binding affinity was validated via molecular dynamics and cellular assays. Pharmacokinetics were profiled in SD rats; metabolic efficacy was evaluated in B6/ob and DIO mice (CT130 biweekly vs semaglutide weekly). Receptor trafficking dynamics and cholesterol regulation were dissected mechanistically. Toxicology was assessed in rodents and a primate pilot study. RESULTS: = 21 pM) and exhibited a prolonged half‑life (13.9 h, 1.4‑fold vs semaglutide). Biweekly CT130 outperformed weekly semaglutide in body weight reduction, glucose tolerance, TC, LDL‑C, body fat percentage and other metabolic indicators. Drug‑free intervals enabled near‑complete GLP‑1R recycling, termed "GLP‑1R recovery", preserving receptor homeostasis, whereas semaglutide drove progressive internalization. CT130 also alleviated constipation risk (increased fecal water) and uniquely lowered cholesterol by suppressing SREBP‑2, which upregulated LDLR while decoupling from PCSK9 induction, thereby promoting fecal cholesterol excretion without altering bile acid flux. No pathological changes were observed even at tens to 200 times the semaglutide dose. In monkeys, two biweekly doses induced > 10% weight loss with good safety. CONCLUSIONS: CT130 is a safe, once biweekly preclinical candidate that incorporates drug free intervals to allow GLP 1R restore. It delivers robust, lasting metabolic benefits with improved gastrointestinal tolerability, and offering a template for next generation long acting GLP 1R agonists.
No takes yet. Share an insight, caveat, or question.
Ding et al. (2026) studied Obesity and metabolic disorders (preclinical models). CT130 (biweekly GLP-1R agonist) vs. Semaglutide (0.312 mg/kg q3d in B6/ob mice; 0.0624 mg/kg q3d in DIO mice) and vehicle control was evaluated on Total fat-to-body weight ratio in DIO mice (p=<0.05 vs semaglutide; <0.0001 vs model).
Synapse has enriched 10 related papers. Consider them for comparative context: